Synergistic pharmaceutical intelligence.

Pharmaceutical access decisions rarely rest on one source. Regulatory history, HTA assessments, clinical findings, economics and published NHS activity each answer a different question. Synapptiq connects them so market access, HEOR and commercial teams can examine the access position, prepare payer discussions and challenge planning assumptions.

What the name means

Synapptiq stands for Synergistic Application of Targeted Pharmaceutical Intelligence.

• Synergistic - each connected source adds context the others lack. An appraisal recommendation frames published NHS activity; NHS activity shows what an appraisal cannot.
• Application - the evidence is applied to a named decision: a payer discussion, an evidence strategy, an account plan or a launch scenario.
• Targeted - every finding stays tied to its medicine, indication, population, comparator and period.
• Pharmaceutical intelligence - connected, source-linked evidence that colleagues can scrutinise before they rely on it.

The name also echoes the synapse, the junction where neurones connect - the idea behind the brain that introduces this site.

Connected evidence, distinct conclusions

Connecting evidence should not blur important boundaries. Regulatory authorisation is not an HTA recommendation. Recorded NHS activity is not proof of clinical effectiveness. A scenario estimate is not an established finding. Synapptiq supports your team's judgement by keeping sources, scope and assumptions open to examination; the Governance page explains how.

Pulsar Developments Limited

Synapptiq is developed and operated by Pulsar Developments Limited, based in Wokingham, England.

Unit 8B, Millars Brook, Molly Millars Lane, Wokingham, RG41 2AD, United Kingdom.

Email: help@pulsardevelopments.com. Telephone: 01189 795319.